NCT07167511

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication

Efficacy and Safety of Bismuth-containing Quadruple Therapy for First Line Helicobacter Pylori Eradication: A Multicenter Retrospective Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,730 (actual)
• Sponsor: Yueyue Li · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Bismuth-containing quadruple therapy was recommended as a first-line treatment for Helicobacter pylori infection. This study aimed to compare real-world outcomes of various bismuth-containging quadruple regimens and identify factors influencing treatment failure. A multicenter retrospective analysis was conducted and study outcomes included eradication rates and incidence of adverse events.

Conditions

• Helicobacter Pylori Infection

Interventions

Type	Name	Description
OTHER	This study is a retrospective study, and all data have been collected in advance with no active intervention required.	This study is a retrospective study, and all data have been collected in advance with no active intervention required.

Timeline

• Start date: 2022-01-01
• Primary completion: 2024-12-31
• Completion: 2025-07-31
• First posted: 2025-09-11
• Last updated: 2025-09-11

Locations

1 site across 1 country: China